Vistagen Therapeutics, Inc.
corporate_fare Company Profile
Vistagen Therapeutics, Inc. (NASDAQ:VTGN) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 33 items for VTGN at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-13, rated 8/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 10 rated 8 or above. Recent SEC coverage for VTGN spans 10-Q, 8-K, 10-K.
Recent high-impact activity:
- Vistagen 10-Q: $20.0M Cash, Going Concern Doubt, Nasdaq Deadline Feb 1, 2027
- Vistagen Cuts Quarterly Loss to $10.7M but Cash Only Funds Operations Into 2027
- Vistagen Wins FDA Backing for LSAS Endpoint in Future Phase 3 of Fasedienol
- Vistagen Cuts 31% of Workforce to Preserve Cash for Fasedienol Phase 3
- Vistagen Expands Executive Severance Plan to Cover Terminations Without Change in Control
Financial Snapshot
Short Interest & Short Volume
3.42 days to coverFINRA reported short interest of 2,488,148 shares in VTGN as of the October 30, 2026 settlement, a 0.6% increase from the prior period — about 3.4 days to cover at its recent average daily volume. On November 20, 2026, 34.2% of VTGN volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.